Bill Text: NY S06103 | 2019-2020 | General Assembly | Introduced
Bill Title: Relates to advertising by drug manufacturers and the disclosure of clinical trials; defines terms; regulates advertisements; requires the disclosure of clinical trials of prescription drugs; makes related provisions.
Spectrum: Partisan Bill (Democrat 1-0)
Status: (Introduced - Dead) 2020-01-08 - REFERRED TO HEALTH [S06103 Detail]
Download: New_York-2019-S06103-Introduced.html
STATE OF NEW YORK ________________________________________________________________________ 6103 2019-2020 Regular Sessions IN SENATE May 16, 2019 ___________ Introduced by Sen. CARLUCCI -- read twice and ordered printed, and when printed to be committed to the Committee on Health AN ACT to amend the public health law, in relation to advertising by drug manufacturers and the disclosure of clinical trials The People of the State of New York, represented in Senate and Assem- bly, do enact as follows: 1 Section 1. The public health law is amended by adding a new section 2 277-a to read as follows: 3 § 277-a. Prohibitions and required disclosures; prescription drug 4 advertising. 1. Definitions. As used in this section, unless the context 5 otherwise indicates, the following terms shall have the following mean- 6 ings: 7 (a) "Clinical trial" means a clinical investigation as defined by the 8 federal Food and Drug Administration that involves any trial to test the 9 safety or efficacy of a drug or biological product with one or more 10 human subjects and that is intended to be submitted to, or held for 11 inspection by, the federal Food and Drug Administration as part of an 12 application for a research or marketing permit. 13 (b) "Manufacturer of prescription drugs" or "manufacturer" means a 14 manufacturer of prescription drugs or biological products or an affil- 15 iate of the manufacturer or a labeler that receives prescription drugs 16 or biological products from a manufacturer or wholesaler and repackages 17 those drugs or biological products for later retail sale and that has a 18 labeler code from the federal Food and Drug Administration under 21 Code 19 of Federal Regulations, 2027.20 (1999). 20 (c) "Regulated advertisement" means the presentation to the general 21 public of a commercial message regarding a prescription drug or biolog- 22 ical product by a manufacturer of prescription drugs that is: 23 (i) Broadcast on television or radio from a station that is physically 24 located in the state; 25 (ii) Broadcast over the Internet from a location in the state; or EXPLANATION--Matter in italics (underscored) is new; matter in brackets [] is old law to be omitted. LBD11791-01-9S. 6103 2 1 (iii) Printed in magazines or newspapers that are printed, distributed 2 or sold in the state. 3 2. Regulated advertisement requirement. Beginning October fifteenth, 4 two thousand twenty, a manufacturer may not present or cause to be 5 presented in the state a regulated advertisement, unless such advertise- 6 ment meets the requirements concerning misbranded drugs and devices and 7 prescription drug advertising of federal law and regulations under 21 8 United States Code, Sections 331 and 352(n) and 21 Code of Federal Regu- 9 lations, Part 202 and state rules and regulations. 10 3. Disclosure of clinical trials of prescription drugs. Beginning 11 October fifteenth, two thousand twenty, a manufacturer or labeler of 12 prescription drugs that is required to report marketing costs for 13 prescription drugs shall post, with regard to such prescription drugs, 14 on the publicly accessible Internet website of the federal National 15 Institutes of Health or its successor agency or another publicly acces- 16 sible website the following information concerning any clinical trial 17 that the manufacturer conducted or sponsored on or after October 18 fifteenth, two thousand nineteen: 19 (a) The name of the entity that conducted or is conducting the clin- 20 ical trial; 21 (b) A summary of the purpose of the clinical trial; 22 (c) The dates during which the trial is taking or has taken place; and 23 (d) Information concerning the results of the clinical trial, includ- 24 ing potential or actual adverse effects of the drug. 25 In order to satisfy the requirements of this subdivision, the publicly 26 accessible website and manner of posting shall be acceptable to the 27 department. 28 4. Fees. Beginning April first, two thousand twenty-one, each manufac- 29 turer of prescription drugs that are provided to persons through a state 30 public health plan as defined in subdivision eleven of section two 31 hundred seventy of this article shall pay a fee of one thousand dollars 32 per calendar year to the department. Fees collected under this subdivi- 33 sion shall be used to cover the cost of overseeing implementation of 34 this section, including but not limited to maintaining links to publicly 35 accessible websites to which manufacturers are posting clinical trial 36 information under subdivision three of this section and other relevant 37 sites, assessing whether and the extent to which New York residents have 38 been harmed by the use of a particular drug and undertaking the public 39 education initiative under subdivision five of this section. Revenues 40 received under this subdivision must be deposited into a general fund to 41 be used for the purposes of this section. 42 5. Public education initiative. The department shall undertake a 43 public education initiative to inform residents of the state about clin- 44 ical trials and drug safety information. 45 6. Penalties. Each day a manufacturer is in violation of this chapter 46 is considered a separate violation. Such manufacturer shall be subject 47 to the penalties prescribed in section twelve of this chapter. 48 § 2. Report. By January 15, 2021, the department of health shall 49 report to the Legislature matters on the completeness and ease of public 50 access to information provided by the drug manufacturers and the need 51 for further action or legislation. 52 § 3. This act shall take effect on the one hundred eightieth day after 53 it shall have become a law. Effective immediately, the addition, amend- 54 ment and/or repeal of any rule or regulation necessary for the implemen- 55 tation of this act on its effective date are authorized to be made and 56 completed on or before such effective date.